From September, 2017, WHO will accept applications for prequalification into their Essential Medicines List for biosimilar versions of two biologics: rituximab (for non-Hodgkin's lymphoma) and trastuzumab (for breast cancer). This pilot project is an effort to increase access to these costly cancer treatments in low-income countries.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2r5yRh3
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Objectives Patients undergoing osteoporosis treatment benefit greatly from early detection. We previously developed a computer-...
-
Publication date: Available online 20 March 2018 Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology Author(s): Tobia...
-
Cerebral Microbleeds: Imaging and Clinical Significance. Radiology. 2018 Apr;287(1):11-28 Authors: Haller S, Vernooij MW, Kuij...
-
Chicago's other mag mile: The second-highest-grossing shopping district in the city is a two-mile stretch of 26th Street on the Southwes...
-
IJMS, Vol. 19, Pages 177: Fusion Proteins of NKG2D/NKG2DL in Cancer Immunotherapy International Journal of Molecular Sciences doi: 10.3390/...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου